|
1
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kanwar RK, Cheung CH, Chang JY and Kanwar
JR: Recent advances in anti-survivin treatments for cancer. Curr
Med Chem. 17:1509–1515. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Akgul C: Mcl-1 is a potential therapeutic
target in multiple types of cancer. Cell Mol Life Sci.
66:1326–1336. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Szegedi I, Katona K, Horváth A, Molnár A,
Aradi J and Kiss C: Bcl-2 antisense oligonucleotide inhibits the
proliferation of childhood leukemia/lymphoma cells of the B-cell
lineage. Pathol Oncol Res. 14:275–279. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chanan-Khan A: Bcl-2 antisense therapy in
hematologic malignancies. Curr Opin Oncol. 16:581–585. 2004.
View Article : Google Scholar
|
|
6
|
Chen Y and Huang L: Tumor-targeted
delivery of siRNA by non-viral vector: safe and effective cancer
therapy. Expert Opin Drug Deliv. 5:1301–1311. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Walchli S and Sioud M: Vector-based
delivery of siRNAs: in vitro and in vivo challenges. Front Biosci.
13:3488–3493. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gondi CS and Rao JS: Concepts in in vivo
siRNA delivery for cancer therapy. J Cell Physiol. 220:285–291.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roelz R, Pilz IH, Mutschler M and Pahl HL:
Of mice and men: human RNA polymerase III promoter U6 is more
efficient than its murine homologue for shRNA expression from a
lentiviral vector in both human and murine progenitor cells. Exp
Hematol. 38:792–797. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang F, Tong X, Fu L and Zhang R:
Knockdown of STAT3 by shRNA inhibits the growth of CAOV3 ovarian
cancer cell line in vitro and in vivo. Acta Biochim Biophys Sin.
40:519–525. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baris D and Zahm SH: Epidemiology of
lymphomas. Curr Opin Oncol. 12:383–394. 2000. View Article : Google Scholar
|
|
12
|
Lai SR and Andrews LG: Tollefsbol To RNA
interference using a plasmid construct expressing short-hairpin
RNA. Methods Mol Biol. 405:31–37. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brummelkamp TR, Bemards R and Agami R: A
system for stable expression of short interfering RNAs in mammalian
cells. Science. 296:550–553. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Paddision PJ, Caudy AA, Bernstein E, et
al: Short hairpin RNAs (shRNAs) induce sequence-specific silencing
in mammalian cells. Genes Dev. 16:948–958. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Y, Zhang CL, Zeng BF, et al: Enhanced
chemosensitivity of drug-resistant osteosarcoma cells by
lentivirus-mediated Bcl-2 silencing. Biochem Biophys Res Commun.
390:642–647. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sastry L, Johnson T, Hobson MJ, et al:
Titering lentiviral vectors: comparison of DNA, RNA and marker
expression methods. Gene Ther. 9:1155–1162. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kuhn DM, Balkis M, Chandra J, et al: Uses
and limitation of the XTT assay in studies of Candidar growth and
metabolism. J Clin Microbiol. 41:506–508. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seol JY, Park KH, Hwang C, et al:
Adenovirus-TRAIL can overcome TRAIL resistance and induce a
bystander effect. Cancer Gene Ther. 10:540–548. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang X, Lin T, Gu J, et al: Cell to cell
contact required for bystander effect of the TNF-related
apoptosis-inducing ligand (TRAIL) gene. Int J Oncol. 22:1241–1245.
2003.PubMed/NCBI
|
|
20
|
Vaux DL, Cory S and Adams JM: BCL-2 gene
promotes haemopoietic cell survival and cooperates with c-myc to
immortalize pre-B cells. Nature. 335:440–442. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Paoluzzi L and O’Connor OA: Targeting
survival pathways in lymphoma. Adv Exp Med Biol. 687:79–96. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chipuk JE, Moldoveanu T, Llambi F, et al:
The BCL-2 family reunion. Mol Cell. 37:299–310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gross A: BCL-2 proteins: regulators of the
mitochondrial apoptotic program. IUBMB Life. 52:231–236. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Llambi F and Green DR: Apoptosis and
oncogenesis: give and take in the BCL-2 family. Curr Opin Genet
Dev. 21:12–20. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu KW, Huang J, Lin TX, et al: The effects
of RNA interference to Bcl-2 gene on proliferation of human bladder
cancer cell line T24. Chin J Urol. 28:26–29. 2007.
|
|
26
|
Lei XY, Yan CY, Tu YL, et al: Inhibition
of Bcl-2 gene expression by siRNA in HL-60 cells. Chinese Pharmacol
Bull. 21:1445–1449. 2005.
|
|
27
|
Ramanarayanan J, Hernandez-Ilizalitu FJ,
Chanan-Khan A and Czuczman MS: Pro-apoptotic therapy with the
oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2
protein expression enhances the biological anti-tumour activity of
rituximab. Br J Haematol. 127:519–530. 2004. View Article : Google Scholar
|
